Everolimus-Eluting Versus Biolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus

Gyldenkerne, Christine; Olesen, Kevin Kris Warnakula; Jensen, Lisette Okkels; Junker, Anders; Veien, Karsten Tange; Terkelsen, Christian Juhl; Kristensen, Steen Dalby; Thim, Troels; Jensen, Svend Eggert; Raungaard, Bent; Aarøe, Jens; Kahlert, Johnny; Villadsen, Anton Boel; Bøtker, Hans Erik; Christiansen, Evald Høj; Mæng, Michael

doi:10.1016/j.amjcard.2019.05.060

Cited by 9 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is a recognized modeling method to induce DN by high glucose in podocytes (Liang et al, 2020; Tu et al, 2019). In the study of Xiaojie Wang et al, a cell model of DM induced by high glucose in podocytes was presented (Gyldenkerne et al, 2019). In our paper, we induced DN in podocytes by 30 mM high glucose, and the model was successfully constructed as we found that oxidative stress and inflammation levels in the cells were increased significantly after high glucose induction, with the occurrence of cell apoptosis and injury.…”

Section: Discussionmentioning

confidence: 99%

“…Our study also demonstrated the important role of STAT1 signaling pathway in DN. At present, most studies are focusing on the clinical efficacy of macrolides for DM, but there are still no reports on the mechanism of macrolides (Gyldenkerne et al, 2019). Our paper found that AZM inhibited the activation of the STAT1 signaling pathway in high glucose‐induced podocytes at the cellular level.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Azithromycin inhibited oxidative stress and apoptosis of high glucose‐induced podocytes by inhibiting STAT1 pathway

Xing

Liu

2021

Drug Development Research

View full text Add to dashboard Cite

Azithromycin (AZM) has a therapeutic effect on diabetes, but there is no report on whether AZM has a therapeutic effect on diabetic nephropathy (DN) and its specific mechanism. Cell survival was detected by CCK‐8. The expression of the inflammatory factors TNF‐α, IL‐1β, and IL‐6 was determined by ELISA. The expression of inflammatory proteins MCP‐1, NLPR3, and ASC was detected by western blot. The expression of MDA, LDH, and SOD was detected by the appropriate kit. Apoptosis was detected by flow cytometry and apoptosis‐related proteins Bcl‐2, Bax, Caspase‐3, 6, 9, and Cleaved caspase‐3, 6, 9 were detected by western blot. In addition, the expression of STAT1 was detected by western blot. AZM can increase the activity of high glucose‐induced podocytes (p < .05). After high glucose induction, the expression of TNF‐α, IL‐1β, and IL‐6 was increased and the expression of MCP‐1, NLPR3, and ASC proteins was also increased (p < .001). When AZM was added, the expression of all the above‐mentioned proteins was decreased (p < .001). In addition, MDA, LDH, and SOD were increased after high glucose induction, while decreased after AZM treatment (p < .001). AZM can inhibit apoptosis and the expression of Bax and Cleaved caspase‐3, 6, 9, and promote the expression of Bcl‐2 (p < .001). Furthermore, the expression of STAT1 was increased after high glucose induction, while the expression of STAT1 was decreased after AZM action (p < .01). By adding a STAT1 agonist IFN‐γ, the effects of AZM on inflammation, oxidative stress, and apoptosis of high glucose‐induced podocytes were inhibited (p < .05). AZM inhibited inflammation, oxidative stress, and apoptosis of high glucose‐induced podocytes by inhibiting STAT1 pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Azithromycin inhibited oxidative stress and apoptosis of high glucose‐induced podocytes by inhibiting STAT1 pathway

Xing

Liu

2021

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…There was an absolute difference of 2.1% in favor of the Synergy stent (3.6% vs. 5.7%) although the difference was statistically nonsignificant. 27 The present SORT OUT X DM substudy found TLF rates of 9.3% and 4.8% among patients with DM in the DTS group and the SES group, respectively. Thus, the TLF rate was almost twice as high in the DTS group compared to the SES group, and the difference reached statistical significance in spite of the relatively low number of patients in each group.…”

Section: Discussionmentioning

confidence: 53%

Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

Jakobsen

Christiansen

Freeman

et al. 2022

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

Objectives: To compare the efficacy and safety of the dual therapy CD34 antibodycovered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study.Background: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with DM when compared to patients without DM. Thus, whether the results from the SORT OUT X study apply to patients with and without DM remains unknown.Methods: In total 3146 patients were randomized to stent implantation with DTS (n = 1578; DM: n = 279) or SES (n = 1568; DM: n = 271). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.Results: At 1 year, the rate of TLF was increased in the DTS group compared to the SES group, both among patients with DM (9.3% vs. 4.8%; risk difference: 4.5%; incidence rate ratio: 1.99, 95% confidence interval [CI]: 1.02-3.90) and without DM (5.7% vs. 3.5%; incidence rate ratio: 1.67, 95% CI: 1.15-2.42). The differences were mainly explained by higher rates of TLR.

show abstract

“…We can only speculate that differences in ischemia assessment, namely the measurement of fractional flow reserve, could have played a role in the observed difference in target lesion revascularization between diabetic patients of EVOLVE II [11] and BIO-RESORT. The SORT OUT VIII trial, a randomized public registry-based all-comers study, compared the very thin strut biodegradable polymer EES with a thicker strut biodegradable polymer biolimus-eluting stent, and included a total of 512 diabetic patients of whom at 1-year follow-up the biodegradable polymer EES-treated patients showed a non-significantly lower rate of target lesion failure (3.6% vs. 5.7%, respectively) [16]. Overall, diabetic patients treated with the very thin strut biodegradable polymer EES showed low event rates, suggesting its use is safe and efficacious in this high-risk subgroup.…”

Section: Previous Studiesmentioning

confidence: 99%

“…Several randomized clinical trials have demonstrated the safety and efficacy of PCI with contemporary drug-eluting stents (DES) in all-comer patients [6][7][8][9][10]. However, in patients with diabetes there is limited evidence that supports the use of contemporary DES, such as the Orsiro sirolimus-eluting stent (SES; Biotronik, Bülach, Switzerland), the Synergy everolimus-eluting stent (EES; Boston Scientific, Marlborough, MA), and the Resolute Integrity zotarolimus-eluting stent (RI-ZES; Medtronic, Santa Rosa, CA) [11][12][13][14][15][16][17]. Furthermore, no outcome data have been published about the treatment of diabetic patients with the most recent iteration of the zotarolimus-eluting stent, the Resolute Onyx (RO-ZES; Medtronic).…”

Section: Introductionmentioning

confidence: 99%

Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials

Ploumen

Buiten

Kok

et al. 2021

International Journal of Cardiology

View full text Add to dashboard Cite

Background Patients with diabetes have more extensive coronary disease, resulting in higher risks of adverse clinical events following stenting. In all-comer patients, contemporary DES have shown excellent safety and efficacy, but data on diabetic patients are scarce. Separately for the BIO-RESORT and BIONYX trials, we assessed the 2-year clinical outcomes of diabetic patients, treated with various contemporary drug-eluting stents (DES). Methods We performed two prespecified secondary analyses of two randomized DES trials, which both stratified for diabetes. The main endpoint was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization. Follow-up was finished before the COVID-19 pandemic. Results In BIO-RESORT, 624/3514 (17.8%) had diabetes: 211 received SES, 203 Synergy everolimus-eluting stents (EES), and 210 Resolute Integrity zotarolimus-eluting stents (RI-ZES). TVF did not differ between SES (10.2%) and EES (10.0%) versus RI-ZES (12.7%) (SES vs. RI-ZES HR:0.78, 95%-CI [0.44–1.40]; p = 0.40, EES vs. RI-ZES HR:0.79, 95%-CI [0.44–1.40]; p = 0.42). In BIONYX, 510/2488 (20.5%) patients had diabetes: 250 received SES and 260 Resolute Onyx zotarolimus-eluting stents (RO-ZES). There was no difference in TVF between SES (10.7%) versus RO-ZES (12.2%) (HR:0.88, 95%-CI [0.52–1.48]; p = 0.63). Conclusions There was no difference in 2-year clinical outcome among patients with diabetes, who were treated with SES, or EES, versus RI-ZES. In addition there was no difference in clinical outcome in diabetic patients, who were treated with SES versus RO-ZES. These findings may be considered as a signal of safety and efficacy of the studied DES in patients with diabetes.

show abstract

Everolimus-Eluting Versus Biolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus

Cited by 9 publications

References 17 publications

Azithromycin inhibited oxidative stress and apoptosis of high glucose‐induced podocytes by inhibiting STAT1 pathway

Azithromycin inhibited oxidative stress and apoptosis of high glucose‐induced podocytes by inhibiting STAT1 pathway

Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials

Contact Info

Product

Resources

About